| Literature DB >> 33806156 |
Tatyana Ilyicheva1,2, Vasily Marchenko1, Olga Pyankova1, Anastasia Moiseeva1, Tran Thi Nhai3, Bui Thi Lan Anh3, Trinh Khac Sau3, Andrey Kuznetsov3, Alexander Ryzhikov1, Rinat Maksyutov1.
Abstract
To cause a pandemic, an influenza virus has to overcome two main barriers. First, the virus has to be antigenically new to humans. Second, the virus has to be directly transmitted from humans to humans. Thus, if the avian influenza virus is able to pass the second barrier, it could cause a pandemic, since there is no immunity to avian influenza in the human population. To determine whether the adaptation process is ongoing, analyses of human sera could be conducted in populations inhabiting regions where pandemic virus variant emergence is highly possible. This study aimed to analyze the sera of Vietnamese residents using hemagglutinin inhibition reaction (HI) and microneutralization (MN) with A/H5Nx (clade 2.3.4.4) influenza viruses isolated in Vietnam and the Russian Federation in 2017-2018. In this study, we used sera from 295 residents of the Socialist Republic of Vietnam collected from three groups: 52 samples were collected from households in Nam Dinh province, where poultry deaths have been reported (2017); 96 (2017) and 147 (2018) samples were collected from patients with somatic but not infectious diseases in Hanoi. In all, 65 serum samples were positive for HI, at least to one H5 virus used in the study. In MN, 47 serum samples neutralizing one or two viruses at dilutions of 1/40 or higher were identified. We postulate that the rapidly evolving A/H5Nx (clade 2.3.4.4) influenza virus is possibly gradually adapting to the human host, insofar as healthy individuals have antibodies to a wide spectrum of variants of that subtype.Entities:
Keywords: H5N6 (clade 2.3.4.4); highly pathogenic avian influenza virus; human sera
Year: 2021 PMID: 33806156 PMCID: PMC8064466 DOI: 10.3390/pathogens10040394
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1The phylogenetic tree for HA of A(H5Nx) influenza viruses. Viruses used in this study are indicated by rhombs. Candidate vaccine viruses are indicated by circles (according to WHO recommendations https://www.who.int/influenza/vaccines/virus/characteristics_virus_vaccines/en/, accessed on 5 March 2021).
HI test of H5Nx clade 2.3.4.4 viruses with ferret reference antisera and horse red blood cells.
| Virus | Subtype | Clade | Reverse Titer with Antisera | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A/duck/England/36254/ | A/Northern Pintail/WA/40964/2014 | A/Sichuan/26221/2014 RG42A | A/gyrfalcon/WA/41088/2014 RG43A | A/great crested grebe/Tyva/34/2016 | A/wigeon/Sakha/1/2014 | A/chicken/SergiyevPosad/ | A/chicken/Kostroma/1718/ | A/common gull/Saratov/1676/2018 | A/chicken/Nghe An/27VTC/2018 | |||
| A/duck/England/36254/2014 | H5N8 | 2.3.4.4c |
| 5120 | 5120 | 640 | 1280 | 1280 | 1280 | 2560 | NA | NA |
| A/Northern Pintail/WA/40964/2014 | H5N2 | 2.3.4.4c | 320 |
| 2560 | 2560 | 640 | 640 | 160 | 1280 | <20 | <20 |
| A/Sichuan/26221/2014 RG42A | H5N6 | 2.3.4.4a | 640 | 5120 |
| 320 | 640 | 320 | 320 | 1280 | <20 | NA |
| A/gyrfalcon/WA/41088/2014 RG43A | H5N8 | 2.3.4.4c | 640 | 5120 | 1280 |
| 1280 | 1280 | 320 | 1280 | <20 | <20 |
| A/great crested grebe/Tyva/34/2016 | H5N8 | 2.3.4.4b | 320 | 5120 | 2560 | 2560 |
| 640 | 640 | 1280 | <20 | <20 |
| A/wigeon/Sakha/1/2014 | H5N8 | 2.3.4.4c | 640 | 10,240 | 2560 | 5120 | 640 |
| 640 | 2560 | <20 | <20 |
| A/chicken/SergiyevPosad/38/2017 | H5N8 | 2.3.4.4b | 160 | 2560 | 2560 | 2560 | 320 | 640 |
| 1280 | <20 | <20 |
| A/chicken/Kostroma/1718/2017 | H5N2 | 2.3.4.4b | 320 | 10,240 | 2560 | 2560 | 640 | 640 | 320 |
| <20 | <20 |
| A/common gull/Saratov/1676/2018 | H5N6 | 2.3.4.4h | <20 | <20 | 80 | <20 | <20 | <20 | <20 | <20 |
| 80 |
| A/chicken/NgheAn/27VTC/2018 | H5N6 | 2.3.4.4h | <20 | 320 | 40 | 20 | <20 | <20 | <20 | <20 | 320 |
|
| A/chicken/NgheAn/01VTC/2018 | H5N6 | 2.3.4.4h | NA | 640 | 80 | <20 | <20 | <20 | <20 | <20 | 320 | 160 |
| A/chicken/Vietnam/NCVD-15A59/2015 | H5N6 | 2.3.4.4f | 320 | 10,240 | 2560 | 2560 | 640 | 640 | 160 | 640 | 40 | <20 |
HI titers of sera with a homologous viruses are highlighted in bold.
MN and HI test of human sera with H5 avian influenza viruses.
| Human Serum Sample | Group | A/chicken/ | A/chicken/ | A/chicken/ | A/common Gull/Saratov/1676/2018 (H5N6) | ||||
|---|---|---|---|---|---|---|---|---|---|
| HI | MN | HI | MN | HI | MN | HI | MN | ||
| 20 | 1 | ≥160 | |||||||
| 56 | 2 | 40 | |||||||
| 60 | 2 | 40 | |||||||
| 82 | 2 | 40 | |||||||
| 100 | 2 | 40 | 40 | ||||||
| 105 | 2 | 80 | |||||||
| 128 | 2 | 40 | 40 | ||||||
| 134 | 2 | 40 | |||||||
| 200 | 3 | ≥160 | ≥160 | ≥160 | 160 | 160 | 80 | ||
| 203 | 3 | 80 | 80 | 160 | 160 | 80 | ≥160 | 80 | |
| 209 | 3 | ≥160 | 80 | 160 | ≥160 | 160 | ≥160 | 160 | |
| 212 | 3 | ≥160 | 160 | 80 | 80 | ≥160 | 160 | ||
| 213 | 3 | ≥160 | 160 | 160 | 80 | ≥160 | 80 | ||
| 214 | 3 | ≥160 | 160 | 160 | 80 | ≥160 | 80 | ||
| 221 | 3 | 80 | ≥160 | 80 | 80 | ≥160 | 160 | ||
| 222 | 3 | 40 | 160 | 40 | 80 | 80 | 80 | ||
| 231 | 3 | 40 | |||||||
| 232 | 3 | 40 | |||||||
| 235 | 3 | 80 | 160 | 160 | 320 | ≥160 | 80 | ||
| 237 | 3 | 80 | ≥160 | 160 | 320 | ≥160 | 160 | ||
| 239 | 3 | 80 | 160 | 40 | 80 | 160 | 160 | ||
| 240 | 3 | ≥160 | ≥160 | 160 | 80 | ≥160 | 320 | ||
| 241 | 3 | ≥160 | 160 | 160 | 80 | ≥160 | 320 | ||
| 250 | 3 | 80 | ≥160 | 80 | 80 | 160 | 160 | ||
| 251 | 3 | 40 | 160 | ||||||
| 255 | 3 | ≥160 | ≥160 | ≥160 | 80 | ≥160 | 320 | ||
| 257 | 3 | ≥160 | ≥160 | 80 | 80 | 80 | 160 | ||
| 258 | 3 | ≥160 | ≥160 | 160 | 80 | ≥160 | 160 | ||
| 259 | 3 | ≥160 | ≥160 | 160 | 160 | ≥160 | 160 | ||
| 268 | 3 | ≥160 | ≥160 | 80 | 160 | ≥160 | 80 | ||
| 270 | 3 | 80 | ≥160 | 40 | 80 | 80 | |||
| 271 | 3 | ≥160 | ≥160 | 80 | 160 | ≥160 | 80 | ||
| 272 | 3 | ≥160 | ≥160 | 80 | 160 | ≥160 | |||
| 273 | 3 | 80 | ≥160 | 80 | 80 | ≥160 | 320 | ||
| 274 | 3 | 80 | ≥160 | 80 | 80 | ≥160 | 80 | ||
| 275 | 3 | ≥160 | ≥160 | ≥160 | 160 | ≥160 | |||
| 277 | 3 | 40 | 40 | ||||||
| 278 | 3 | ≥160 | 160 | 80 | 160 | ≥160 | 80 | ||
| 281 | 3 | ≥160 | ≥160 | 80 | 160 | 160 | |||
| 283 | 3 | ≥160 | 80 | 80 | 80 | ≥160 | |||
| 284 | 3 | ≥160 | ≥160 | ≥160 | 160 | ≥160 | |||
| 285 | 3 | ≥160 | ≥160 | 320 | ≥160 | ||||
| 286 | 3 | ≥160 | ≥160 | 80 | 160 | ≥160 | |||
| 287 | 3 | ≥160 | 80 | 80 | 80 | ≥160 | |||
| 288 | 3 | 80 | 40 | ≥160 | |||||
| 289 | 3 | ≥160 | ≥160 | 160 | 160 | ≥160 | |||
| 290 | 3 | 80 | 80 | 80 | 80 | 80 | |||
| 291 | 3 | 80 | 160 | 160 | 80 | ≥160 | |||
| 292 | 3 | 80 | ≥160 | 160 | 80 | ≥160 | |||
| 293 | 3 | 80 | 160 | 80 | 80 | ≥160 | |||
| 294 | 3 | 80 | ≥160 | 80 | 80 | ≥160 | |||
| 295 | 3 | 80 | 160 | 80 | 80 | ≥160 | |||
| 296 | 3 | 80 | 160 | 40 | 40 | ||||
| 297 | 3 | 40 | 40 | 40 | |||||
| 298 | 3 | 40 | 80 | ||||||
| 299 | 3 | 80 | 80 | 80 | 160 | 80 | |||
| 300 | 3 | 80 | 80 | 80 | 160 | 80 | |||
| 303 | 3 | 40 | 80 | 40 | 80 | ||||
| 304 | 3 | 40 | 80 | 160 | |||||
| 307 | 3 | 40 | 80 | 40 | 160 | ||||
| 308 | 3 | 80 | 80 | 80 | 80 | 80 | 160 | ||
| 309 | 3 | 40 | ≥160 | 40 | 80 | 40 | |||
| 310 | 3 | 40 | 80 | 40 | 40 | ||||
| 334 | 3 | 80 | 80 | 80 | 80 | 160 | 40 | ||
| 335 | 3 | 80 | 80 | 80 | 160 | 80 | 80 | ||
| 338 | 3 | 80 | 80 | 80 | 160 | 40 | 80 | ||
| 339 | 3 | 80 | 80 | 80 | 160 | 80 | |||
| Total number of positive sera | 59 | 2 | 65 | 1 | 51 | 47 | 54 | 27 | |
Reciprocal serum titers are shown for the selected sera positive in HI and MN simultaneously at least for one virus. The positive serum in MN ≥ 40, the positive serum in HI test ≥ 40. Each serum was tested three times in HI test with horse red blood cells; the results differed by no more than 2 times, and a lower value was taken for the serum titer. Sera from recovered ferrets infected with analyzed virus strain were used as a positive control. Negative control was represented by sera of non-immune ferrets and human sera without antibodies to avian influenza virus. Negative control titer in all tests > 20, positive control titer from 320 to 640.